IL1B and deep vein thrombosis: These data are interesting since several data implicate IL1β in the pathogenesis of ATH, and it has been used as a therapeutic target in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) in about 10,000 patients who have sustained a prior myocardial infarction [31].